| scholarly article | Q13442814 |
| P50 | author | Alexander M. M. Eggermont | Q28317101 |
| Jean-Charles Soria | Q33120580 | ||
| P2093 | author name string | Jean Charles Soria | |
| Stéphane Champiat | |||
| Charles Ferté | |||
| Sophie Lebel-Binay | |||
| P2860 | cites work | Cancer genome landscapes | Q22242276 |
| A small-cell lung cancer genome with complex signatures of tobacco exposure | Q24600510 | ||
| Mutational heterogeneity in cancer and the search for new cancer-associated genes | Q24606956 | ||
| Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Signatures of mutational processes in human cancer | Q29547191 | ||
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape | Q29620881 | ||
| Mutations induced by ultraviolet light | Q34400112 | ||
| Translating tumor antigens into cancer vaccines | Q34484042 | ||
| Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. | Q34988072 | ||
| Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab | Q35289145 | ||
| Mechanisms underlying UV-induced immune suppression | Q36062334 | ||
| CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases | Q36846646 | ||
| Genomic landscape of non-small cell lung cancer in smokers and never-smokers | Q36851245 | ||
| "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy | Q37697126 | ||
| Inflammation and immune surveillance in cancer | Q37972527 | ||
| Exploiting the mutanome for tumor vaccination. | Q39413641 | ||
| Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma | Q42874163 | ||
| Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. | Q44204596 | ||
| Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers | Q60634938 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e27817 | |
| P577 | publication date | 2014-01-16 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy | |
| P478 | volume | 3 |
| Q41306256 | A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes |
| Q26827701 | Acquired and intrinsic resistance in cancer immunotherapy |
| Q38981383 | Advances in immunotherapy for the treatment of glioblastoma |
| Q39007525 | Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. |
| Q50300666 | Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer |
| Q51079342 | Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ. |
| Q26774312 | Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches |
| Q52614487 | Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer |
| Q92666578 | Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay |
| Q52385841 | Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic |
| Q57291659 | CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges |
| Q50481939 | CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 pha |
| Q49835188 | Challenging Standard-of-Care Paradigms in the Precision Oncology Era. |
| Q38819030 | Characterization of MHC Class I and β-2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials |
| Q37525422 | Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells |
| Q42314661 | Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. |
| Q36498243 | Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. |
| Q64298027 | Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis |
| Q38759770 | Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. |
| Q90289571 | Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma |
| Q26799117 | Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment |
| Q59477539 | Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations |
| Q47360357 | Current and future therapeutic approaches for osteosarcoma. |
| Q46635839 | Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations. |
| Q28075322 | Developmental therapeutics for inflammatory breast cancer: Biology and translational directions |
| Q47617121 | Dramatic response to nivolumab in xeroderma pigmentosum skin tumor. |
| Q65002602 | Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis. |
| Q58595922 | Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer |
| Q43225522 | Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme. |
| Q38362051 | Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies |
| Q38330237 | Genomic discoveries in adult astrocytoma |
| Q37181493 | HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival |
| Q38706874 | HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model |
| Q33930588 | High sensitivity of cancer exome-based CD8 T cell neo-antigen identification |
| Q38926293 | High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma |
| Q37676297 | IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting |
| Q38743793 | Immune Checkpoint Inhibitors in Gliomas. |
| Q92285498 | Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer |
| Q92433126 | Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events |
| Q38856570 | Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer |
| Q37125088 | Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma |
| Q39312652 | Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack |
| Q49166036 | Immune system and melanoma biology: a balance between immunosurveillance and immune escape. |
| Q39308337 | Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options |
| Q92503954 | Immunotherapy in breast cancer |
| Q37050960 | Immunotherapy in glioblastoma: emerging options in precision medicine |
| Q52723409 | Immunotherapy in previously treated non-small cell lung cancer (NSCLC). |
| Q49787333 | Implications of KRAS mutations in acquired resistance to treatment in NSCLC. |
| Q37637243 | Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. |
| Q35446009 | Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses |
| Q88013125 | Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers |
| Q37295260 | Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections |
| Q55654316 | Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. |
| Q55156621 | Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. |
| Q92312371 | Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report |
| Q47903730 | Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. |
| Q50321985 | Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. |
| Q26740988 | New targeted treatments for non-small-cell lung cancer - role of nivolumab |
| Q35200532 | Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer |
| Q39646977 | Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer |
| Q48149391 | Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. |
| Q41508440 | Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer |
| Q29620913 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer |
| Q92660093 | Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy |
| Q97532341 | Novel Immunotherapeutic Approaches in Head and Neck Cancer |
| Q36173439 | Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. |
| Q37017190 | Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. |
| Q38578968 | Overview of KRAS-Driven Genetically Engineered Mouse Models of Non-Small Cell Lung Cancer |
| Q38642853 | PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. |
| Q33839204 | PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. |
| Q38765760 | PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future |
| Q47135594 | PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level |
| Q89287784 | Pediatric Cancer Immunotherapy: Opportunities and Challenges |
| Q38938285 | Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer |
| Q37078999 | Prioritization schema for immunotherapy clinical trials in glioblastoma |
| Q92289292 | Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma |
| Q30240241 | Prognostic factors in follicular lymphoma: new tools to personalize risk |
| Q38774624 | Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review |
| Q47094413 | Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis |
| Q38948905 | Progress and opportunities for immune therapeutics in osteosarcoma |
| Q56888903 | RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade |
| Q36305457 | Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? |
| Q37053820 | Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer |
| Q41613025 | Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review |
| Q38378172 | Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation |
| Q36316627 | Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. |
| Q50033731 | The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective |
| Q92214210 | The current state of molecular testing in the treatment of patients with solid tumors, 2019 |
| Q38715265 | The impact of sequencing on diagnosis and treatment of malignant melanoma |
| Q92424807 | The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base |
| Q90281646 | The prognostic value of tumor mutational burden and immune cell infiltration in esophageal cancer patients with or without radiotherapy |
| Q52805099 | The role of Next-Generation Sequencing in tumoral radiosensitivity prediction |
| Q38260633 | Translational biology of osteosarcoma |
| Q48228133 | Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy |
| Q89802562 | [Osteoid-forming bone tumors : Morphology and current translational cell biology] |
Search more.